M
Marina Nechaeva
Publications - 31
Citations - 834
Marina Nechaeva is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 8, co-authored 17 publications receiving 288 citations.
Papers
More filters
Journal ArticleDOI
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Ahmet Sezer,Saadettin Kilickap,Mahmut Gumus,Igor Bondarenko,Mustafa Ozguroglu,Miranda Gogishvili,Haci Mehmet Turk,Irfan Cicin,Dmitry Bentsion,Oleg Gladkov,Philip Clingan,Virote Sriuranpong,Naiyer A. Rizvi,Bo Gao,Siyu Li,S. Lee,Kristina McGuire,Chieh I. Chen,Tamta Makharadze,Semra Paydas,Marina Nechaeva,Frank Seebach,David M. Weinreich,George D. Yancopoulos,Giuseppe Gullo,Israel Lowy,P. Rietschel +26 more
TL;DR: In this paper, the first-line treatment of advanced non-small-cell lung cancer with programmed cell death ligand 1 (PD-L1) of at least 50% was examined in a multicentre, open-label, global, phase 3 study.
Journal ArticleDOI
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100.
Markus Moehler,Mikhail Dvorkin,Narikazu Boku,Mustafa Ozguroglu,Min Hee Ryu,Alina Muntean,Sara Lonardi,Marina Nechaeva,Arinilda Silva Campos Bragagnoli,Hasan Şenol Coşkun,Antonio Cubillo Gracian,Toshimi Takano,Rachel Wong,Howard Safran,Gina M. Vaccaro,Zev A. Wainberg,Matthew R. Silver,Huiling Xiong,Janet Hong,Julien Taieb,Yung-Jue Bang +20 more
TL;DR: Gastric 100 did not demonstrate superior OS with avelumab maintenance versus continued chemotherapy in patients with advanced GC or GEJC overall or in a prespecified PD-L1–positive population.
Proceedings ArticleDOI
Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer
Leisha A. Emens,Sherene Loi,HS Rugo,Andreas Schneeweiss,Véronique Diéras,H. Iwata,Carlos Barrios,Marina Nechaeva,Luciana Molinero,A Nguyen Duc,Roel Funke,S.Y. Chui,Amreen Husain,EP Winer,Sylvia Adams,Peter Schmid +15 more
TL;DR: Exploratory efficacy analyses from IMpassion130 suggest consistency between local and central ER/PR/HER2 testing and that PD-L1 IC is the most robust predictive biomarker for selecting untreated mTNBC pts who benefit from A-nabPx.
Journal ArticleDOI
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Rebecca Kristeleit,Alla Lisyanskaya,A. Fedenko,Mikhail Dvorkin,Andreia Cristina de Melo,Yaroslav Shparyk,I. R. Rakhmatullina,Igor Bondarenko,Nicoletta Colombo,Valentyn Svintsitskiy,L.S. Biela,Marina Nechaeva,Domenica Lorusso,Giovanni Scambia,David Cibula,Róbert Póka,Ana Oaknin,Tamar Safra,Beata Mackowiak-Matejczyk,Linglan Ma,Daleen Thomas,Kevin K. Lin,Karen Mclachlan,Sandra Goble,Amit M. Oza +24 more
TL;DR: In this article , the authors compared poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors to chemotherapy for the treatment of BRCA1-mutated (BRCA2)-mutated ovarian carcinoma.
Journal ArticleDOI
FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma
Salah-Eddin Al-Batran,Martin Schuler,Zanete Zvirbule,Georgiy Manikhas,Florian Lordick,Andriy Rusyn,Yuriy Vynnyk,Ihor Vynnychenko,Natalia Fadeeva,Marina Nechaeva,Assen Dudov,Evgeny Gotovkin,Alexander Pecheniy,Igor Bazin,Igor Bondarenko,Bohuslav Melichar,Christian Mueller,Christoph Huber,Ö. Türeci,Ugur Sahin +19 more
TL;DR: IMAB362 is a chimeric monoclonal antibody that mediates specific killing of CLDN18.2-positive cancer cells by activation of immune effector mechanisms and has demonstrated single-agent activity and was safe and tolerable in patients with pretreated gastric cancer.